ZLDPF Zealand Pharma A/S

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 24 / 2025

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit .

Contact

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email:

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email:

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

Attachment



EN
05/12/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Wim Lewi
FAGR FAGRON SA
ZLDPF ZEALAND PHARMA A/S
EKOP EKOPAK NV
12h / 31m 12h / 31m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Model update, multiple important catalysts ahead

We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...

ZLDPF ZEALAND PHARMA A/S
13h 13h 1 EN
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
ZLDPF ZEALAND PHARMA A/S
SHUR SHURGARD SELF STORAGE LIMITED
01/09/26 January 9, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...

Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.

ZLDPF ZEALAND PHARMA A/S
01/09/26 January 9, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch